title: Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab.
authors.forename: Y
authors.initials: Y
authors.lastname: Allanore
authors.forename: G
authors.initials: G
authors.lastname: Devos-François
authors.forename: C
authors.initials: C
authors.lastname: Caramella
authors.forename: P
authors.initials: P
authors.lastname: Boumier
authors.forename: V
authors.initials: V
authors.lastname: Jounieaux
authors.forename: A
authors.initials: A
authors.lastname: Kahan
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000150:complications* / Q000000981:diagnostic imaging; D012595:Scleroderma, Systemic / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy; D014057:Tomography, X-Ray Computed; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab